Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trialsHiddo J.L. Heerspink, Tom Greene, Hocine Tighiouart et al.|The Lancet Diabetes & Endocrinology|2019Cited by 372
Cystic phenotype and chronic kidney disease in autosomal dominant Alport syndromeTeresa Bada-Bosch, Manuel Praga, Amir Shabaka et al.|Nephrology Dialysis Transplantation|2024Cited by 13
Lipidomics Unveils Critical Lipid Pathway Shifts in Alport SyndromeBelén Requena, Gema Fernández‐Juárez, Amir Shabaka et al.|Kidney International Reports|2025Cited by 4
Microangiopatía trombótica como recidiva de síndrome antifosfolípido en trasplante renalTeresa Bada-Bosch, Amado Andrés, Beatríz Redondo et al.|Nefrología|2019Cited by 2
Primary antiphospholipid syndrome presented as thrombotic microangiopathy in renal transplantationTeresa Bada-Bosch, Marina Alonso, Beatríz Redondo et al.|Nefrología (English Edition)|2020Cited by 0